Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
Recent: |
|
Past: |
|
Britain should be taxing unhealthy food and clamping down on marketing, says Sarah Boseley, the Guardian’s former health editor → Read More
Tobacco companies are pouring money into e-cigarettes and making them attractive to teens, says Sarah Boseley, the Guardian’s former health editor → Read More
CAB-LA injections offer stigma-free protection for those at risk – particularly women in Africa. A deal with pharmaceutical companies is crucial → Read More
It’s immoral to delay curbs on dangerous meals and blame the cost of living crisis, says Sarah Boseley, former health editor of the Guardian → Read More
Remember flu? Despite lockdowns holding it at bay, a small group of scientists is searching the globe for deadly new strains – and to work out what to put in next winter’s vaccines → Read More
I’ve travelled the world covering everything from HIV to MMR to Ebola… and then Covid came along. These are stories that changed me – and the world → Read More
Amid bemusement from scientists at the deluge of often undeserved criticism, the Guardian pieces together the story behind the vaccine’s successes and failures → Read More
BAT and Imperial Tobacco deny they are responsible for farming families’ exploitation → Read More
The Guardian’s health editor, Sarah Boseley, weighs up the race between vaccines and variants and explains why the end of the pandemic does not mean the end of Covid-19 → Read More
Oxford University trial reports cocktail of manmade antibodies reduces fatalities by a fifth → Read More
UK has ordered 60m doses of vaccine that is also critical part of effort to vaccinate developing world → Read More
At least 1bn doses due from G7 but campaigners say package does not address structural problems → Read More
Group of scientists contest privacy concerns that they say are hampering research into illnesses such as long Covid → Read More
Achieving herd immunity is possible – and necessary – but requires quick action, say experts → Read More
Usefulness of aducanumab is disputed but US approval will trigger push to make it available globally → Read More
Former PMs, presidents and ministers sign letter saying richest should pay two-thirds of $66bn needed → Read More
Call follows the approval of Pfizer jab for 12-to 15-year olds and Delta variant outbreaks in English schools → Read More
Analysis: the Pfizer/BioNTech jab has been approved for 12-15 year-olds but the risk-benefit equation is more complex than it is for for adults → Read More
Decision that jab is safe and effective potentially paves way for vaccination campaign in schoolchildren → Read More
Top scientist Jeremy Farrar calls on Boris Johnson to use G7 presidency to take global lead on dose sharing → Read More